SCHEMBL632952

SCHEMBL632952

COCCNc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNH3 Q9ULD8 5/20 0.62
MAPT P10636 3/20 0.56
ALDH1A1 P00352 2/20 0.56
NCF1 P14598 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.48
MALT1 Q9UDY8 1/20 0.47
LDHA P00338 1/20 0.46
RORC P51449 1/20 0.46
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.44
USP2 O75604 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9015900 0.88 KCNH3 (0.51) KCNH3MAPTALDH1A1NCF1L3MBTL1
SCHEMBL14982724 0.88 KCNH3 (0.51) KCNH3MAPTALDH1A1NCF1L3MBTL1
SCHEMBL3681897 0.88 KCNH3 (0.51) KCNH3MAPTALDH1A1NCF1L3MBTL1
SCHEMBL6646246 0.87 ALDH1A1 (0.64) KCNH3MAPTALDH1A1L3MBTL1GAA
SCHEMBL11637357 0.85 MAPT (0.61) KCNH3MAPTALDH1A1L3MBTL1GAA
SCHEMBL5556493 0.85 RORC (0.52) KCNH3MAPTALDH1A1NCF1L3MBTL1
SCHEMBL11637424 0.84 MAPT (0.59) KCNH3MAPTALDH1A1L3MBTL1GAA
SCHEMBL11634715 0.84 MAPT (0.59) KCNH3MAPTALDH1A1L3MBTL1GAA
SCHEMBL5013171 0.83 KCNH3 (0.47) KCNH3MAPTALDH1A1NCF1MALT1
SCHEMBL3248804 0.81 ALDH1A1 (0.61) KCNH3MAPTALDH1A1L3MBTL1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-0790818-B1 KERATIN FIBRE OXIDATION DYEING COMPOSITION AND DYEING METHOD USING SAME OREAL (FR) 2001-05-30 EP claimed
US-6030984-A 7-(4-PHENOXYPHENYL)-6-OXOQUINOLIZINES AND DERIVATIVES OF TRICYCLIC RING ANALOGUES, PARTICULARLY 7-OXOTHIENO-(2,3-A)QUINOLIZINE; INHIBITING BETA-AMYLOID PEPTIDE ACTIVITY HOFFMANN-LA ROCHE INC. (US) 2000-02-29 US claimed
US-5869500-A INHIBITING BETA-AMYLOID PEPTIDE ACTIVITY HOFFMANN-LA ROCHE INC. (US) 1999-02-09 US claimed
WO-1998025930-A2 USE OF BI- AND TRICYCLIC PYRIDONE DERIVATIVES AGAINST ALZHEIMER'S DISEASE F. HOFFMANN-LA ROCHE AG (CH) 1998-06-18 WO claimed
EP-0294669-B1 METAPHENYLENDIAMINES, PROCESS FOR THEIR PREPARATION, INTERMEDIATE COMPOUNDS AND USE OF THESE METAPHENYLENDIAMINES AS COUPLERS IN OXYDATIVE COLOURING OF KERATINIC FIBRES ESPECIALLY OF HUMAN HAIR L'OREAL (FR) 1991-07-17 EP claimed
EP-0295474-B1 CHLOROMETAPHENYLENEDIAMINES, THEIR USE AS COUPLING AGENTS IN OXYDATION COLOURING OF KERATINIC FIBRES, COLOURITY COMPOSITIONS FOR HAIR CONTAINING THESE COMPOUNDS AND COLOURING PROCESS USING THESE COMPOSITIONS L'OREAL (FR) 1991-07-17 EP claimed
EP-0416962-A1 Keratinous fibers dyeing process with indole dyes and oxidation dye precursors and dyeing agents L'OREAL (FR) 1991-03-13 EP claimed
EP-0295474-A1 Chlorometaphenylenediamines, their use as coupling agents in oxydation colouring of keratinic fibres, colourity compositions for hair containing these compounds and colouring process using these compositions L'OREAL (FR) 1988-12-21 EP claimed
EP-0294669-A1 Metaphenylendiamines, process for their preparation, intermediate compounds and use of these metaphenylendiamines as couplers in oxydative colouring of keratinic fibres especially of human hair L'OREAL (FR) 1988-12-14 EP claimed
EP-4692072-A1 PHOTOCHROMIC COMPOUND, PROPARGYL ALCOHOL COMPOUND, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND SPECTACLES TOKUYAMA CORPORATION (JP) 2026-02-11 EP disclosed
EP-4692071-A1 PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASS TOKUYAMA CORPORATION (JP) 2026-02-11 EP disclosed
EP-4688148-A1 SELECTIVE RAPAMYCIN ANALOGS AND USES THEREOF Regeneron Pharmaceuticals, Inc. (US) 2026-02-11 EP disclosed
EP-4370207-B1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES INC (US) 2025-12-17 EP disclosed
US-4048154-A POLYAMIDE FIBERS BAYER AKTIENGESELLSCHAFT (DT) 1977-09-13 US disclosed
US-4028323-A WITH A SUBSTITUTED AMINOBENZENE CIBA-GEIGY AG (CH) 1977-06-07 US disclosed
US-3987026-A POLYESTERS CIBA-GEIGY CORPORATION (US) 1976-10-19 US disclosed
US-3964862-A Process for dyeing and printing textile materials of synthetic organic fibers CIBA-GEIGY AG (CH) 1976-06-22 US disclosed
US-3945991-A Heterocyclic azo compounds containing a quaternated hydrazide group CIBA-GEIGY AG (CH) 1976-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL KCNH3 896/4885MAPT 4621/4885ALDH1A1 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.